For Healthcare Professionals Only

See what’s possible in COPD

YUPELRI – the first and only once-daily nebulized LAMA
for the maintenance treatment of COPD

YUPELRI inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).



YUPELRI is Now Available!

Up to 100% coverage expected through Medicare Part B*
• Universal J-code: 7699
• NDC# 49502-806-93
*Site of care will determine applicable Medicare coverage. This is not a guarantee of coverage.

Register now

Connect with us for news and updates about managing COPD and prescribing YUPELRI


*All fields required

*
*
*
*
*

By clicking the “Submit” button below, you will automatically be enrolled in our email program.

Mylan understands that your patients' health information, as well as your personal and professional information, is private. All information you provide will only be used by Mylan and trusted parties acting on its behalf to send you materials you requested and other helpful information and special offers about YUPELRI, as well as related treatments, products, offers and services. You may opt out of receiving these communications at any time. Should you decide to receive additional information from Mylan and YUPELRI, please note that this website is intended for residents of the United States. As such, by opting-in to receive our communications, you confirm that you are a resident of the United States and eligible to receive such communications.

To learn about how Mylan Specialty uses your information, please view our Privacy Statement.

Important Safety Information

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

Indication

YUPELRI inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


Please see the full Prescribing Information.

For additional information please contact us at 800-395-3376.

Important Safety Information

See more See Less

YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.


YUPELRI is contraindicated in patients with hypersensitivity to revefenacin or any component of this product.

YUPELRI should not be initiated in patients during acutely deteriorating or potentially life-threatening episodes of COPD, or for the relief of acute symptoms, i.e., as rescue therapy for the treatment of acute episodes of bronchospasm. Acute symptoms should be treated with an inhaled short-acting beta2-agonist.

As with other inhaled medicines, YUPELRI can produce paradoxical bronchospasm that may be life-threatening. If paradoxical bronchospasm occurs following dosing with YUPELRI, it should be treated immediately with an inhaled, short-acting bronchodilator. YUPELRI should be discontinued immediately and alternative therapy should be instituted.

YUPELRI should be used with caution in patients with narrow-angle glaucoma. Patients should be instructed to immediately consult their healthcare provider if they develop any signs and symptoms of acute narrow-angle glaucoma, including eye pain or discomfort, blurred vision, visual halos or colored images in association with red eyes from conjunctival congestion and corneal edema.

Worsening of urinary retention may occur. Use with caution in patients with prostatic hyperplasia or bladder-neck obstruction and instruct patients to contact a healthcare provider immediately if symptoms occur.

Immediate hypersensitivity reactions may occur after administration of YUPELRI. If a reaction occurs, YUPELRI should be stopped at once and alternative treatments considered.

The most common adverse reactions occurring in clinical trials at an incidence greater than or equal to 2% in the YUPELRI group, and higher than placebo, included cough, nasopharyngitis, upper respiratory infection, headache and back pain.

Coadministration of anticholinergic medicines or OATP1B1 and OATP1B3 inhibitors with YUPELRI is not recommended.

YUPELRI is not recommended in patients with any degree of hepatic impairment.

Indication

YUPELRI inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).


Please see the full Prescribing Information.

For additional information please contact us at 800-395-3376.

I%20thought%20this%20might%20interest%20you-%20FDA%20Approved%20YUPELRI™%20(revefenacin)%20inhalation%20solution
YUPELRI%20%28revefenacin%29%20inhalation%20solution%20is%20now%20FDA%20Approved%E2%80%94Learn%20more%20at%20YUPELRIHCP.com.%0A%0ASee%20the%20full%20Prescribing%20Information%20and%20Medication%20Guide.%0A%0AFor%20additional%20information%20please%20contact%20us%20800-395-3376.%0A